‘Emerging Treatment Strategies for Motor Fluctuation Management: Therapeutic Options for Newly Detected Motor Fluctuations’ reviews a series of posters on the topic of Parkinson’s disease (PD) presented at the 7th Congress of the European Academy of Neurology (EAN) 2021. Posters presented included real-world data on the efficacy and safety of emerging treatments for patients with PD, with a focus on opicapone (ONGENTYS®, Bial, Trofa, Portugal), a catechol-O-methyltransferase inhibitor developed to manage motor fluctuations, symptoms that severely impact patient quality of life.
Latest articles
All articles
18 Mins
27
Jan
New Advances in the Treatment of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy
Both spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are monogenic neuromuscular diseases, which cause progressive proximal-to-distal muscular weakness, leading to loss of motor function and related pulmonary and musculoskeletal co-morbidities and reduced survival.